Press release

Siemens Healthineers posts strong revenue and profit growth in the second quarter

  • Second-quarter revenue rises 5.8 percent on a comparable basis
  • Adjusted profit up 12 percent; adjusted profit margin at 17.9 percent
  • Outlook for fiscal year 2019 confirmed

"The positive volume and profit development in the last quarter underscores the important progress we have made in achieving our full-year targets. The numbers once again underline the competitive strength of the entire Siemens Healthineers team. The Imaging and Advanced Therapies businesses in particular have again demonstrated their leading global positions. The measures taken to ensure a successful market launch of our laboratory diagnostics platform Atellica Solution have shown an early impact in the second quarter”, said Bernd Montag, CEO of Siemens Healthineers AG.

As expected Siemens Healthineers AG's growth clearly accelerated in the second quarter of the current fiscal year 2019 that started in October. On a comparable basis, meaning excluding currency translation and portfolio effects, revenue rose 5.8 percent from the previous year and reached EUR 3.5 billion. Growth was particularly driven by the Imaging and Advanced Therapies segments, with EMEA and China recording significant growth from a regional perspective. On a reported basis, revenue was up about nine percent. Thanks to a significant increase in profitability in Imaging and Advanced Therapies, adjusted profit1 rose 12 percent year on year to EUR 627 million. This translates into an adjusted profit margin of 17.9 percent in the second quarter, compared to 17.4 percent a year earlier and despite negative currency effects of 70 basis points. Net income rose 24 percent to EUR 381 million despite a higher tax rate. The increase was supported by the absence of costs for the IPO in the previous year. Basic earnings per share increased accordingly2. Based on the business performance in the first six months of the year, the company confirms its outlook for fiscal year 2019.

Siemens Healthineers reporting segments in second quarter
Revenue of the Imaging segment rose to EUR 2.1 billion in the second quarter, corresponding to an increase of about seven percent from a year earlier on a comparable basis. This performance was supported by all reporting regions, with significant growth in EMEA and strong growth in the Americas region. Looking at individual businesses, particularly Molecular Imaging, Computed Tomography and X-Ray Products showed a strong development. The Imaging segment’s adjusted profit margin rose to 21.0 percent, mainly due to higher revenue and cost savings. Profitability thus remained within the midterm target range of 20 to 22 percent.

In the Diagnostics segment, second-quarter revenue was up about two percent on a comparable basis, supported by growth in the Asia, Australia and EMEA reporting regions, and reached just over EUR 1 billion. The segment’s adjusted profit margin reached 11.8 percent and, as in the first quarter, was negatively impacted by currency effects and ramp-up costs for Atellica Solution3. More than 410 Atellica Solution analyzers were shipped in the three months ending March 31, with the cumulated number for the first six months totaling over 780 shipments. In the meantime, Atellica Solution has also received approval in China.

The Advanced Therapies segment recorded revenue of EUR 391 million in the second quarter. On a comparable basis, this corresponds to an increase of around nine percent compared with the prior-year quarter. All reporting regions contributed to this performance, with the Asia, Australia and EMEA regions recording significant growth. At 19.6 percent, the adjusted profit margin was well above the prior-year figure, mainly due to higher revenue and cost savings.

Outlook for fiscal year 2019
The company confirms the outlook for fiscal year 2019 and continues to expect comparable revenue growth to be in the range of four to five percent compared to fiscal year 2018 and an adjusted profit margin in the range of 17.5 to 18.5 percent. Earnings per share are expected to be 20 to 30 percent above the level of fiscal year 2018. The outlook assumes that current foreign exchange rates persist for all of the remaining fiscal year 2019.


Link to the related press feature

 

Q2 2019

Q2 2018

Actual change

Revenue

3,505

3,226

9%

Profit

616

457

35%

…Margin

17.6%

14.2%

340 bps

Adjusted profit

627

560

12%

…Margin

17.9%

17.4%

50 bps

Net income

381

308

24%

Basic earnings per share in EUR

0.38

0.30

24%

Free cash flow

204

174

17%

 

Q2 2019

Q2 2018

Actual change

Imaging

 

 

 

…Total revenue

2,137

1,946

10%

…Profit

441

371

19%

…Profit margin

20.7%

19.1%

160 bps

…Adjusted profit margin

21.0%

19.3%

170 bps

Diagnostics

 

 

 

…Total revenue

1,018

970

5%

…Profit

119

125

(5%)

…Profit margin

11.7%

12.9%

(120 bps)

…Adjusted profit margin

11.8%

13.6%

(180 bps)

Advanced Therapies

 

 

 

…Total revenue

391

352

11%

…Profit

75

55

35%

…Profit margin

19.1%

15.7%

340 bps

…Adjusted profit margin

19.6%

16.0%

360 bps

1

2

3

Siemens Healthineers 2018

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide.